1. 毕业设计（论文）的内容和要求

癌症是全球死亡的主要原因之一，迫切需要先进的治疗技术。

新型纳米材料和纳米载体的开发已经为改善癌症中的药物递送提供了主要驱动力。

大多数纳米载体应用的主要目的是保护药物在全身递送后免于被快速降解，并允许其以达到治疗浓度到达肿瘤部位，同时尽可能避免药物递送至正常部位以减少不利影响。

2. 参考文献

[1] B.A. Chabner, P.C. Amrein, B.J. Druker, M.D. Michaelson, C.S. Mitsiades, P.E.Goss, D.P. Ryan, S. Ramachandra, P.G. Richardson, J.G. Supka, W.H. Wilson, Antineoplastic agents, in: L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.), Goodman Gilman抯 The Pharmacological Basis of Therapeutics, Mc Graw Hill, New York, 2006, pp. 1357?359. [2] A.J. Primeau, A. Rendon, D. Hedley, L. Lilge, I.F. Tannock, Clin. Cancer Res. 11 (2005) 8782?788. [3] O. Tr閐an, C.M. Galmarini, K. Patel, I.F. Tannock, J. Natl. Cancer Inst. 99 (2007) 1441?454. [4] X.Y. Xu, L. Li, J.P. Zhou, S.Y. Lu, J. Yang, X.J. Yin, J.S. Ren, Colloids Surf. B 55 (2007) 222?28. [5] X.T. Shuai, H. Ai, N. Nasongkla, S. Kim, J.M. Gao, J. Controlled Release 98 (2004) 415?26. [6] H. Wildiers, R. Jurcut, J. Ganame, L. Herbots, P. Neven, J. De Backer, H. Denys, V. Cocquyt, F. Rademakers, J.U. Voigt, R.A. Paridaens, Crit. Rev. Oncol. Hematol.67 (2008) 133?38. [7] T.P. Formariz, L.A. Chiavacci, V.H.V. Sarmento, C.M. Franzini, A.A. Silva- Jr., M.V. Scarpa, C.V. Santilli, E.S.T. Egito, A.G. Oliveira, Colloids Surf. B 63 (2008) 287?95. [8] F. Li, J. Sun, H. Zhu, X. Wen, C. Lin, D. Shi, Colloids Surf. B 88 (2011) 58. [9] Y.Z. Du, L. Wang, H. Yuan, X.H. Wei, F.Q. Hu, Colloids Surf. B 69 (2009) 257?63. [10] Y. Barenholz, Curr. Opin. Colloid Interface Sci. 6 (2001) 66?7. [11] T. Ishida, M.J. Kirchmeier, E.H. Moase, S. Zalipsky, T.M. Allen, Biochim. Biophys. Acta 1515 (2001) 144?58. [12] J. Shin, P. Shum, D.H. Thompson, J. Controlled Release 91 (2003) 187?00. [13] P. Venugopalan, S. Jain, S. Sankar, P. Singh, A. Rawat, S.P. Vyas, Pharmazie 57 (2002) 659?71. [14] K. Liu, R.R. Xing, Q.L. Zou, G.H. Ma, H. M鰄wald, X.H. Yan, Angew. Chem. Int. Ed. 55 (2016) 1?. [15] H. Zhang, J.B. Fei, X.H. Yan, A.H. Wang, J.B. Li, Adv. Funct. Mater. 25 (2015) 1193?204. [16] T.L. Andresen, S.S. Jensen, K. Jorgensen, Prog. Lipid Res. 44 (2005) 68?7. [17] M.B. Yatvin, W. Kreutz, B.A. Horwitz, M. Shinitzky, Science 210 (1980) 1253?255. [18] D.C. Drummond, M. Zignani, J. Leroux, Prog. Lipid Res. 39 (2000) 409?60. [19] S.K. Huang, E. Mayhew, S. Gilani, D.D. Lasic, F.J. Martin, D. Papahadjopoulos, Cancer Res. 52 (1992) 6774?781. [20] M. Dellian, G. Helmlinger, F. Yuan, R.K. Jain, Br. J. Cancer 74 (1996) 1206?215. [21] G. Helmlinger, F. Yuan, M. Dellian, R.K. Jain, Nat. Med. 3 (1997) 177?82. [22] G. Helmlinger, A. Schell, M. Dellian, N.S. Forbes, R.K. Jain, Clin. Cancer Res. 8 (2002) 1284?291. [23] X.G. Zhang, J. Miao, Y.Q. Dai, Y.Z. Du, H. Yuan, F.Q. Hu, Int. J. Pharm. 361 (2008) 239?44. [24] P. Ma, X.W. Dong, C.L. Swadley, A. Gupte, M. Leggas, H.C. Ledebur, R.J. Mumper, J. Biomed. Nanotechnol. 5 (2009) 151?61. [25] H.L. Wong, R. Bendayan, A.M. Rauth, X.Y. Wu, J. Pharm. Sci. 93 (2004) 1993?004. [26] S.V. Mussi, V.P. Torchilin, J. Mater. Chem. B. 1 (2013) 5201?209. [27]Al-Jamal, W.T., Kostarelos, K., 2011. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Accounts Chem. Res. 44, 1094?104. [28]Hadjidemetriou, M., Al-Ahmady, Z.S., Kostarelos, K., 2016. Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. Nanoscale 8, 6948?957. [29] Sengupta, P., Basu, S., Soni, S., Pandey, A., Roy, B., Oh, M.S., Chin, K.T., Paraskar, A.S., Sarangi, S., Connor, Y., Sabbisetti, V.S., Kopparam, J., Kulkarni, A., Muto, K., Amarasiriwardena, C., Jayawardene, I., Lupoli, N., Dinulescu, D.M., Bonventre, J. V., Mashelkar, R.A., Sengupta, S., 2012. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc. Natl. Acad. Sci. U. S. A. 109, 11294?1299. [30] Wang, H., Chen, W., Xie, H., Wei, X., Yin, S., Zhou, L., Xu, X., Zheng, S., 2014a. Biocompatible, chimeric peptide-condensed supramolecular nanoparticles for tumor cell-specific siRNA delivery and gene silencing. Chem. Commun. 50, 7806?809.

3. 毕业设计（论文）进程安排

2017.12.1-12.5 与导师会面，布置论文题目及要求 12.6-12.22 申报毕业设计题目，下达任务书，做好开题前期工作 12.22-2018.1.12 完成翻译，检索相关文献 1.12-3.1 离子对合成，脂质体系形成 3.2-4.30 材料结构及性质的表征 4.31-5.31 数据整理，书写论文,制作PPT 6.1-6.10 准备论文答辩